%0 Journal Article %A Felipe Olivares %A Daniel Muñoz %A Alberto Fica %A Ignacio Delama %A Ignacia Alvarez %A Maritza Navarrete %A Eileen Blackburn %A Pamela Garrido %A Juan Grandjean %T Covid-19 in Chile. The experience of a Regional reference Center. Preliminary report %D 2020 %R 10.1101/2020.06.14.20130898 %J medRxiv %P 2020.06.14.20130898 %X During the first pandemic wave Covid-19 reached Latin America cities.Aim To report clinical features and outcomes associated to Covid-19 in a group of patients admitted during the first wave in a regional reference Center in southern Chile designated to severe and critical cases.Methods Cases were identified by a compatible clinical picture associated to positive RT-PCR or serological testing. A standard protocol was applied.Results 21 adult patients (20 diagnosed by PCR, one by serology) were admitted between epidemiological weeks 13 to 20, involving 8.8% of total regional cases. Hospitalization occurred at a median of 11 days after symptoms onset. Patients ≥60 years old predominated (57.1%). Hypertension (61.9%), obesity (57.1%) and diabetes mellitus 2 (38.1%) were prevalent but 19% had no comorbid conditions nor were elderly. Two cases involved second-trimester pregnant women. Positive IgM or IgM/IgG results obtained by rapid serological testing were limited (19% at 1st week; 42.9% at 2nd week). Nine patients (42.9%, critical group) were transferred to ICU and connected to mechanical ventilation due to respiratory failure. By univariate analysis admission to ICU was significantly associated to tachypnea and higher plasmatic LDH values. One pregnant woman required urgent cesarean section given birth to a premature neonate without vertical transmission. Two patients died (in-hospital mortality 9.5%) and length of stay was ≥ 14 days in 57.9% of patients.Conclusion In our regional Center, Covid 19 was associated to known risk factors, had a prolonged stay and in-hospital mortality. Tachypnea ≥30/min is predictive of transfer to ICU.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot funding involvedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Comite de Etica Cientifico, Servicio de Salud de Valdivia, Chile Registration Number 155, june 2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available if needed %U https://www.medrxiv.org/content/medrxiv/early/2020/06/16/2020.06.14.20130898.full.pdf